
Zheng-Rong Lu
Education
Research Interests
Novel MRI contrast agents<br>Molecular imaging<br>Drug delivery<br>Therapeutics for treating retinal diseases<br>Gene delivery<br>NanomedicineTeaching Interests
Drug delivery<br>Molecular imaging<br>Nanomedicine<br>Biomolecular EngineeringOther Affiliations
Publications
Affiliated School Research Areas
Affiliated Department Research Areas
News About Zheng-Rong Lu
Zheng-Rong Lu elected fellow of National Academy of Inventors
Case Western Reserve University researcher Zheng-Rong Lu has been elected as a fellow of The National Academy of Inventors (NAI)
Biomedical engineering’s Zheng-Rong Lu named Gund-Harrington Scholar
Lu was selected for his work in developing therapies for retinal degenerative diseases.
Case Comprehensive Cancer Center earns $31.9 million in grants National Cancer Institute
Collaboration across Case Western Reserve, Cleveland Clinic and University Hospitals celebrates 30th anniversary as one of nation’s elite cancer centers.
CWRU team wins National Cancer Institute grant
Biomedical engineering researchers from the Case School of Engineering have teamed up with the Case Western Reserve School of Medicine and Case Comprehensive Cancer center to study early tumor detection with the help of a $1.9-million grant from the National Cancer Institute’s Provocative Questions funding program.
New contrast agent spotlights tiny tumors and micrometastases
Researchers at Case Western Reserve University have developed a magnetic resonance imaging (MRI) contrast agent that detects much smaller aggressive breast cancer tumors and micrometastases
Zheng-Rong Lu In the News
CWRU’s ZR Lu named Gund-Harrington Scholar by the Harrington Discovery Institute
CWRU’s ZR Lu named Gund-Harrington Scholar by the Harrington Discovery Institute
CWRU researchers develop gene-delivery system to stop vision loss.
CWRU researchers develop gene-delivery system to stop vision loss.
CWRU research teams uses nanoparticles to deliver genetic therapy to prevent vision loss.
CWRU research teams uses nanoparticles to deliver genetic therapy to prevent vision loss.
CWRU researchers use nanoparticles to prevent blindness.
CWRU researchers use nanoparticles to prevent blindness.
Imaging agent developed by BME researchers at CWRU distinguishes between aggressive and benign prostate cancer.
Imaging agent developed by BME researchers at CWRU distinguishes between aggressive and benign prostate cancer.